Cover Image
市場調查報告書

進行性多發性腦白質病變:開發中產品分析

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361634
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
進行性多發性腦白質病變:開發中產品分析 Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 39 Pages
簡介

本報告提供進行性多發性腦白質病變治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

進行性多發性腦白質病變概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

進行性多發性腦白質病變:企業開發中的治療藥

進行性多發性腦白質病變:大學/機關研究中的治療藥

進行性多發性腦白質病變:開發中產品概況

  • 初期階段的產品

進行性多發性腦白質病變:企業開發中的產品

進行性多發性腦白質病變:大學/機關研究中的產品

進行性多發性腦白質病變的治療藥的開發企業

  • Neurimmune Holding AG
  • Pomona Ricerca S.R.L

進行性多發性腦白質病變:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

進行性多發性腦白質病變:最近的開發平台趨勢

進行性多發性腦白質病變:暫停中的計劃

進行性多發性腦白質病變:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8761IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 3 respectively.Progressive Multifocal Leukoencephalopathy.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Progressive Multifocal Leukoencephalopathy Overview
  • Therapeutics Development
    • Pipeline Products for Progressive Multifocal Leukoencephalopathy - Overview
    • Progressive Multifocal Leukoencephalopathy - Therapeutics under Development by Companies
  • Progressive Multifocal Leukoencephalopathy - Pipeline Products Glance
    • Early Stage Products
  • Progressive Multifocal Leukoencephalopathy - Products under Development by Companies
  • Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
    • Humabs BioMed SA
    • Neurimmune Holding AG
    • Neuway Pharma GmbH
    • Pomona Ricerca SRL
  • Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • EBT-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IkT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKT-01427 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKT-148009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for JCV and BKV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPW-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNJC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Progressive Multifocal Leukoencephalopathy - Dormant Projects
  • Progressive Multifocal Leukoencephalopathy - Product Development Milestones
    • Featured News & Press Releases
      • May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy
      • Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases
      • Aug 16, 2011: Inhibikase Therapeutics Receives FDA Clearance For Phase II Trial Of IkT-001 To Treat JC Virus Infection In Multiple Sclerosis Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H2 2016
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H2 2016
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H2 2016
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Progressive Multifocal Leukoencephalopathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top